Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: A phase I study

Haematologica

Volumn 92, Issue 7, 2007, Pages 952-959

  Introna, Martino ^a   Borleri, Gianmaria ^a   Conti, Elena ^a   Franceschetti, Marta ^a   Barbui, Anna Maria ^a   Broady, Raewyn ^a   Dander, Erica ^b   Gaipa, Giuseppe ^b   D'Amico, Giovanna ^b   Biagi, Ettore ^b   Parma, Matteo ^c   Pogliani, Enrico M ^c   Spinelli, Orietta ^a   Baronciani, Donatella ^d   Grassi, Anna ^a   Golay, Josée ^a   Barbui, Tiziano ^a   Biondi, Andrea ^b   Rambaldi, Alessandro ^a  

^a OSPEDALI RIUNITI   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d Ospedale Oncologico A Businco   (Italy)

Author keywords

Allo HSCT; CIK; DLI; GVHD

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ADVERSE OUTCOME; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL COUNT; CELL THERAPY; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DISEASE COURSE; DONOR; FEASIBILITY STUDY; FEMALE; HEMATOLOGIC MALIGNANCY; HEMATOLOGY; HODGKIN DISEASE; HUMAN; KILLER CELL; LYMPHOCYTE TRANSFER; MALE; MORTALITY; MYELODYSPLASIA; PATIENT SAFETY; PRE B LYMPHOCYTE; RELAPSE; SALVAGE THERAPY; SIBLING; TREATMENT RESPONSE; ALLOTRANSPLANTATION; BLOOD DISEASE; DRUG EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOCYTE TRANSFUSION; METHODOLOGY; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; RECURRENT DISEASE; TRANSPLANTATION;

ADULT; CYTOKINES; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KILLER CELLS; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; RECURRENCE; SALVAGE THERAPY; TRANSPLANTATION, HOMOLOGOUS;

EID: 34548801834     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11132     Document Type: Article

References (35)

1. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer 2004;4:371-80.
2. Talmadge JE. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy. Int Immunopharmacol 2003;3:1121-43.
3. Campbell JD, Cook G, Holyoake TL. Evolution of bone marrow transplantation-the original immunotherapy. Trends Immunol. 2001;22:88-92.
4. Slavin S, Morecki S, Weiss L, Shapira MY, Resnick I, Or R. Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy-from bench to patient bedside. Semin Oncol 2004;31:4-21.
5. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004;103:767-76.
6. Falkenburg JH, Willemze R. Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia. Best Pract Res Clin Haematol 2004;17:415-25.
7. Introna M, Barbui AM, Golay J, Rambaldi A. Innovative cell-based therapies in onco-hematology: what are the clinical facts? Haematologica 2004;89:1253-60.
8. Ruggeri L, Capanni M, Mancusi A, Aversa F, Martelli MF, Velardi A. Natural killer cells as a therapeutic tool in mismatched transplantation. Best Pract Res Clin Haematol 2004;17:427-38.
9. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-92.
10. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991;9:694-704.
11. Klingemann HG. Natural killer cell-based immunotherapeutic strategies. Cytotherapy 2005;7:16-22.
12. Hercend T, Griffin JD, Bensussan A, Schmidt RE, Edson MA, Brennan A, et al. Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes. J Clin Invest 1985;75:932-43.
13. Griffin JD, Hercend T, Beveridge R, Schlossman SF. Characterization of an antigen expressed by human natural killer cells. J Immunol 1983;130:2947-51.
14. Lanier LL, Testi R, Bindl J, Phillips JH. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med 1989;169:2233-8.
15. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991;174:139-49.
16. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994;153:1687-96.
17. (+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 1998;92:18-27.
18. + cells from peripheral blood progenitor cells or patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2001;7:16-22.
19. (+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood 2001;97: 23-31.
20. Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993;21:1673-79.
21. Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 2002;116:78-86.
22. Sconocchia G, Lau M, Provenzano M, et al. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions. Blood 2005;106:3666-72.
23. + NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant 2001;7:532-42.
24. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 2003;101:640-8.
25. Sweeney TJ, Mailander V, Tucker AA, et al. Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci USA 1999;96:12044-9.
26. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005;11:181-7.
27. Wang FS, Liu MX, Zhang B, Shi M, Lei ZY, Sun WB, et al. Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J Gastroenterol 2002;8:464-8.
28. Shi M, Zhang B, Tang ZR, Lei ZY, Wang HF, Feng YY, et al. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 2004;10:1146-51.
29. Kubat M, Skavic J, Behluli I, Nuraj B, Bekteshi T, Behluli M, et al. Population genetics of the 15 AmpF ISTR Identifiler loci in Kosovo Albanians. Int J Legal Med 2004; 118:115-8.
30. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. Report of an international working group to standardize response criteria for myelodysplasia syndromes. Blood 2000;96:3671-4.
31. + NK-T cells in humans and mice. J Clin Immunol 2002; 22:131-6.
32. Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 2006;107:1325-31.
33. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105:3051-7.
34. Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 2004;103:3065-72.
35. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, et al. Allogeneic cell theraphy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogenic bone marrow transplantation. Blood 1996;87:2195-204.